Anti-NAA15 Antibody
Rabbit polyclonal antibody to NAA15
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IF/IC, IHC |
---|---|
Primary Accession | Q9BXJ9 |
Other Accession | Q80UM3 |
Reactivity | Human, Mouse, Rat |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 101272 Da |
Gene ID | 80155 |
---|---|
Other Names | GA19; NARG1; NATH; TBDN100; N-alpha-acetyltransferase 15, NatA auxiliary subunit; Gastric cancer antigen Ga19; N-terminal acetyltransferase; NMDA receptor-regulated protein 1; Protein tubedown-1; Tbdn100 |
Target/Specificity | Recognizes endogenous levels of NAA15 protein. |
Dilution | WB~~WB (1/500 - 1/1000), IH (1/100 - 1/200), IF/IC (1/100 - 1/500) IH~~WB (1/500 - 1/1000), IH (1/100 - 1/200), IF/IC (1/100 - 1/500) IF~~WB (1/500 - 1/1000), IH (1/100 - 1/200), IF/IC (1/100 - 1/500) |
Format | Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.09% (W/V) sodium azide. |
Storage | Store at -20 °C.Stable for 12 months from date of receipt |
Name | NAA15 |
---|---|
Synonyms | GA19, NARG1, NATH, TBDN100 |
Function | Auxillary subunit of N-terminal acetyltransferase complexes which display alpha (N-terminal) acetyltransferase (NAT) activity (PubMed:15496142, PubMed:20154145, PubMed:29754825, PubMed:32042062). The NAT activity may be important for vascular, hematopoietic and neuronal growth and development (PubMed:15496142). Required to control retinal neovascularization in adult ocular endothelial cells (PubMed:11687548). In complex with XRCC6 and XRCC5 (Ku80), up-regulates transcription from the osteocalcin promoter (PubMed:12145306). |
Cellular Location | Cytoplasm. Nucleus. Note=Mainly cytoplasmic, nuclear in some cases. Present in the free cytosolic and cytoskeleton- bound polysomes, but not in the membrane-bound polysomes |
Tissue Location | Expressed at high levels in testis and in ocular endothelial cells. Also found in brain (corpus callosum), heart, colon, bone marrow and at lower levels in most adult tissues, including thyroid, liver, pancreas, mammary and salivary glands, lung, ovary, urogenital system and upper gastrointestinal tract. Overexpressed in gastric cancer, in papillary thyroid carcinomas and in a Burkitt lymphoma cell line (Daudi). Specifically suppressed in abnormal proliferating blood vessels in eyes of patients with proliferative diabetic retinopathy. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
KLH-conjugated synthetic peptide encompassing a sequence within the center region of human NAA15. The exact sequence is proprietary.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.